AI Engines For more Details: Perplexity Kagi Labs You
Antiparasitic Action: Pyrvinium pamoate works by interfering with the energy metabolism of the pinworms, leading to their paralysis and expulsion from the gastrointestinal tract. It is effective against adult pinworms as well as some larval stages.
Treatment of Pinworm Infections: Pyrvinium pamoate is specifically indicated for the treatment of pinworm infections, which commonly occur in children and can cause symptoms such as anal itching, irritability, and difficulty sleeping. Treatment with pyrvinium pamoate helps to eliminate the worms and alleviate associated symptoms.
Single-Dose Treatment: Pyrvinium pamoate is often administered as a single oral dose, making it convenient for patients and healthcare providers. However, in some cases, multiple doses may be necessary to ensure complete eradication of the pinworm infection.
Safety and Tolerability: Pyrvinium pamoate is generally well-tolerated, with few reported side effects. However, like any medication, it may cause adverse reactions in some individuals, such as gastrointestinal upset (nausea, vomiting, diarrhea), allergic reactions, or skin rash. Serious side effects are rare.
Precautions: Pyrvinium pamoate should be used with caution in patients with liver disease or impairment, as the medication is metabolized in the liver. It is not recommended for use in pregnant or breastfeeding women unless the potential benefits outweigh the risks.
Follow-Up: After treatment with pyrvinium pamoate, it is important for patients to practice good hygiene, including thorough handwashing and washing of bedding and clothing, to prevent reinfection and the spread of pinworms to others.
Consultation with Healthcare Provider: Before using pyrvinium pamoate or any antiparasitic medication, individuals should consult with a healthcare provider for proper diagnosis and treatment guidance. Healthcare providers can provide instructions on dosage, administration, and potential side effects, as well as recommendations for preventing future infections.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.9 | 0.3 | 12 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.7 | 2.3 | 0.17 |
| Allergies | 5.3 | 1.1 | 3.82 |
| Allergy to milk products | 1.3 | 1.6 | -0.23 |
| Alopecia (Hair Loss) | 0.9 | 0.9 | |
| Alzheimer's disease | 4.8 | 5.8 | -0.21 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 0.5 | 2.6 |
| Ankylosing spondylitis | 3.1 | 1.2 | 1.58 |
| Anorexia Nervosa | 1.2 | 2.2 | -0.83 |
| Antiphospholipid syndrome (APS) | 2 | 0.3 | 5.67 |
| Asthma | 4.8 | 1.7 | 1.82 |
| Atherosclerosis | 2.2 | 1.9 | 0.16 |
| Atrial fibrillation | 2.2 | 1.9 | 0.16 |
| Autism | 8.3 | 6.7 | 0.24 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.3 | 2.3 | |
| Bipolar Disorder | 2.1 | 1.1 | 0.91 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.9 | 2.8 | -2.11 |
| Carcinoma | 3.4 | 1.6 | 1.13 |
| Celiac Disease | 3.4 | 2.5 | 0.36 |
| Cerebral Palsy | 1.4 | 0.8 | 0.75 |
| Chronic Fatigue Syndrome | 5.4 | 4.2 | 0.29 |
| Chronic Kidney Disease | 4 | 1.1 | 2.64 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 1.4 | 0.36 |
| Chronic Urticaria (Hives) | 1.9 | 0.6 | 2.17 |
| Coagulation / Micro clot triggering bacteria | 1.8 | 0.8 | 1.25 |
| Cognitive Function | 1.6 | 1.6 | 0 |
| Colorectal Cancer | 6.1 | 2.4 | 1.54 |
| Constipation | 1.5 | 0.5 | 2 |
| Coronary artery disease | 2.3 | 2 | 0.15 |
| COVID-19 | 8.5 | 6.8 | 0.25 |
| Crohn's Disease | 7.9 | 3 | 1.63 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.1 | 1.1 | 0 |
| d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
| deep vein thrombosis | 1.7 | 1.1 | 0.55 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 10.6 | 6.8 | 0.56 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 1.4 | 0.64 |
| Endometriosis | 2.4 | 1.6 | 0.5 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.7 | 1.6 | 1.31 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 2.4 | 1.4 | 0.71 |
| Functional constipation / chronic idiopathic constipation | 5.9 | 3 | 0.97 |
| gallstone disease (gsd) | 3.2 | 1.1 | 1.91 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.8 | 0.3 | 5 |
| Generalized anxiety disorder | 2.8 | 1.7 | 0.65 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.2 | 0.2 | 5 |
| Graves' disease | 1.6 | 2 | -0.25 |
| Gulf War Syndrome | 0.5 | 1.5 | -2 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 2.3 | 0.9 | 1.56 |
| Heart Failure | 3.6 | 0.8 | 3.5 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.8 | 0.3 | 5 |
| hypercholesterolemia (High Cholesterol) | 1 | 1 | |
| hyperglycemia | 1.7 | 1 | 0.7 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 2.8 | 4.4 | -0.57 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 2.9 | 0.3 | 8.67 |
| IgA nephropathy (IgAN) | 1.6 | 4.3 | -1.69 |
| Inflammatory Bowel Disease | 8.6 | 6.6 | 0.3 |
| Insomnia | 0.9 | 1.4 | -0.56 |
| Intelligence | 1.6 | 1.6 | |
| Intracranial aneurysms | 1 | 0.3 | 2.33 |
| Irritable Bowel Syndrome | 6.6 | 4.4 | 0.5 |
| ischemic stroke | 2.7 | 1.4 | 0.93 |
| Liver Cirrhosis | 6.4 | 3 | 1.13 |
| Long COVID | 6.3 | 4.5 | 0.4 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 1.5 | 1.5 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1 | 0.3 | 2.33 |
| ME/CFS with IBS | 1.1 | 0.6 | 0.83 |
| ME/CFS without IBS | 2 | 1.2 | 0.67 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.5 | 0.5 | 2 |
| Metabolic Syndrome | 7.6 | 6.6 | 0.15 |
| Mood Disorders | 10.7 | 5.9 | 0.81 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 6.3 | 3.8 | 0.66 |
| Multiple system atrophy (MSA) | 1.2 | 0.3 | 3 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.8 | -8.33 |
| Neuropathy (all types) | 0.6 | 2.2 | -2.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.9 | 2 | 0.95 |
| NonCeliac Gluten Sensitivity | 1.2 | 0.6 | 1 |
| Obesity | 7.6 | 5.6 | 0.36 |
| obsessive-compulsive disorder | 5.4 | 1.8 | 2 |
| Osteoarthritis | 2.6 | 0.9 | 1.89 |
| Osteoporosis | 2.2 | 0.6 | 2.67 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 6.1 | 4.2 | 0.45 |
| Polycystic ovary syndrome | 5.9 | 2.2 | 1.68 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.6 | 0.4 | 0.5 |
| primary biliary cholangitis | 0.6 | 1.7 | -1.83 |
| Primary sclerosing cholangitis | 3 | 1.8 | 0.67 |
| Psoriasis | 2.8 | 1.9 | 0.47 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.2 | 3.1 | 0.68 |
| Rosacea | 0.3 | 0.7 | -1.33 |
| Schizophrenia | 5.6 | 2 | 1.8 |
| scoliosis | 0.5 | 0.3 | 0.67 |
| Sjögren syndrome | 2.5 | 1.6 | 0.56 |
| Sleep Apnea | 0.6 | 1.1 | -0.83 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.8 | 0.6 | 2 |
| Stress / posttraumatic stress disorder | 2.5 | 2.4 | 0.04 |
| Systemic Lupus Erythematosus | 4.4 | 1.4 | 2.14 |
| Tic Disorder | 1.2 | 0.6 | 1 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 3.7 | 3.2 | 0.16 |
| Type 2 Diabetes | 8.2 | 5.9 | 0.39 |
| Ulcerative colitis | 4.7 | 6.5 | -0.38 |
| Unhealthy Ageing | 4.8 | 1.6 | 2 |
| Vitiligo | 1.9 | 0.9 | 1.11 |
